The Application of mRNA in Treating Cancer
DOI:
https://doi.org/10.61173/whehp021Keywords:
tumor, immunotherapy, mRNA, gene therapyAbstract
Messenger ribonucleic acid (mRNA) immunity and polypeptides, chimeric antigen receptor T cells (CAR T),
deoxyribonucleic acid (DNA) immunity. These drugs have the advantages of simple preparation, low cost, low toxicity,
and high biosafety in cancer immunotherapy. It is an up-and-coming drug candidate for tumor treatment. At present,
many enterprises have the production technology of mRNA vaccines. International pharmaceutical enterprises for
mRNA immunotherapy of cancer are in clinical research and have shown good immune effects in clinical practice.
References
[1] Farkona, S., Diamandis, E. P., and Blasutig, I. M. Cancer immunotherapy: the beginning of the end of cancer?. BMC Med. (2016)14:73.
[2] Lei Mia, Yu Zhang and Leaf Huang. mRNA vaccine for cancer immunotherapy. Open Access. (2021) 20:41.
[3] Granot, Y., and Peer, D. Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin. Immunol. (2017)34:68-77.
[4] Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., and Thakur, A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. (2020).12:102.
[5] Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.Nature. (2016)534:396-401.
[6] Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. (2017)8:14630.
[7] Elizabeth I., Anna M., Alexander K., Marc K. Jenkins. Detection of Dendritic Cell Antigen Presentation to CD4+ T Cells. J Exp Med. (1997)185: 2133-2141.
[8] Alexandra E. G., Stephen B., Jaya S., Courtnee A. C., Victoire C., Dongwook C. C.. A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences. Molecular Therapy—Nucleic Acids (2016) 16: 2162- 2531.
[9] Jan D. Beck et al, mRNA therapeutics in cancer immunotherapy, Molecular Cancer (2021) 20:69
[10] Sasso, J. M., Ambrose, B., Tenchov, R., Datta, R. S. , Basel, M. T. , & Delong, R. K. , et al.. The progress and promise of RNA medicine-an arsenal of targeted treatments. (2022)26:254- 263.
[11] Boczkowski P. Review of Carl Mitcham’s Thinking through technology: The path between engineering and philosophy: Science, Technology, & Human Values. (1996)17:31-37.
[12] Burris HA. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with Dean&Francis pembrolizumab in patients with unresectable solid tumors; (2019)34:803-806.
[13] Ann J. B., Allen Y. J., Peng Z., Richard W. and Daniel G. A.. The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology. (2022)3:840-854.
[14] Barbier, A.J., Jiang, A.Y., Zhang, P. et al. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol (2022)40:840-854.
[15] . Grimmett E., Al-Share B., Alkassab M., Zhou R., Desai A, Rahim M., Woldie I.. Cancer vaccines: past, present and future; a review article. Discov Oncol. (2022)13:31.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
